Click here to close now.


News Feed Item

Five New Human Studies Completed by Greenleaf Medical AB Since 2013 NutrAward Win for Best New Ingredient

Global Leader in Nutraceutical Research and Development Announces Results of Five Human Studies and Two Animal Trials

STOCKHOLM, SWEDEN -- (Marketwired) -- 03/08/14 -- Since winning NutrAward's 'Best New Ingredient' at Nutracon in March 2013, Greenleaf Medical's Appethyl ™ has been the subject of five new successful clinical trials. These five human studies and two animal trials have affirmed both the appetite suppression and weight loss effects found in the original pilot trials.

Appethyl™ is the tradename for the clinically-tested appetite suppression product from spinach that is being brought to the marketplace by Greenleaf Medical (GLM), a Swedish company that has licensed the patented technology from Lund University in Sweden.

In the clinical trials completed in 2013, Appethyl has been shown to provide the following key benefits:

1. Significantly reducing appetite four to six hours after ingesting the product with a meal. In addition, post hoc analysis showed that there was no difference between 3.7g and 7.4g dose as both doses were equally effective in reducing both hunger and thinking about food at four hours.(1)

2. Significantly reducing cravings for sweets after the first dose of 5 g, but even more significantly after 90 days and throughout the entire day.(2)

3. Significant weight loss and fat loss as well as significant loss in waist circumference compared to placebo in a very well-controlled (DBPC), 12 week independent clinical trial utilizing 2.5g given twice daily.(3)

Post-market analysis has also provided additional insights including a common experience being an increase in appetite suppression over three to four days. This effect is interesting since there is published clinical data supporting a significant reduction in appetite after just one dose which is now further supported by another yet to be published clinical trial. In addition, there are many reports of individuals feeling better when they take the product, which may be explained by one of those 100 or so proteins found in the active thylakoids found within Appethyl and one in particular, rubisco.

Two animal trials were also completed in 2013, which helped expand the physiological effects of this proprietary spinach extract. The first trial investigated the effects of Appethyl on the gut flora in rats while the second investigated the effects of Appethyl on CCK and blood glucose and insulin in pigs fed only glucose. The results are summarized below:

1. Rats fed Appethyl™ for just 10 days resulted in a significant prebiotic effect increasing the growth of Lactobacillus reuteri, a beneficial probiotic, as well as producing a completely different fecal flora from that of the control group. In addition, the product was found to significantly reduce food intake as well as a 60% lower plasma insulin levels two hours after ingesting an oral glucose tolerance test (OGTT).(4) The novel prebiotic finding is the basis for a new patent application.

2. Pigs fed Appethyl along with receiving OGTT resulted in significantly lower blood glucose levels within the first hour, greater CCK within just 30 min and an even more significant drop in ghrelin between 2 and 4 hours post-ingestion.(5)

Since the 2013 NutraAward win, Greenleaf Medical celebrated their first product launch of Appethyl in Sweden. Sales numbers surpassed projections, as Appethyl was the number one selling nutraceutical in the largest health food store chain in Sweden within weeks of its introduction to the market. Appethyl sold out in the first few days of its Swedish launch resulting in sales of $1.2 million in the first week in Sweden alone, where the population is only 9.5 million, less than a twentieth of the United States population.

For more information on Appethyl ™ or Greenleaf Medical, please visit or contact Maria Soderberg at +46 70 869 27 06, (GMT +1) email: ms(at)gl-medical(dot)com.

About Greenleaf Medical AB
Greenleaf Medical is a Swedish research and development company, active in the global nutraceutical market, which sells and develops natural ingredients with well-documented, beneficial health effects. Greenleaf Medical works together with universities and international science and regulatory groups. Their products are used in both Functional Food and Dietary Supplements.

Greenleaf Medical believes the secret of health and beauty is based on finding the best ingredients through scientific validation. Dedicated to creating natural products with published mechanism-of-action and efficacy studies, the Greenleaf Medical team believes in the unique composition of natural, active ingredients and innovative formula of their supplements.

(1) Stenblom EL, Montelius C, Ostbring K, Hakansson M, Nilsson S, Rehfeld JF, Erlanson-Albertsson C. Supplementation by thylakoids to a high carbohydrate meal decreases feelings of hunger, elevates CCK levels and prevents postprandial hypoglycaemia in overweight women. Appetite 2013;68:118-23.
(2) Erlanson-Albertsson C, Montelius C, Erlandsson D, Vitija E, Egecioglu E, Podgórski K. Suppressed urge for sweet and release of GLP-1 in overweight women through consumption of green plant thylakoids. Presented at 5th Swiss Winter Conference on Ingestive Behavior, March 3, 2014, St Moritz, Swiss.
(3) Unpublished data.
(4) Montelius C, Osman N, Wstrom B, Ahrne S, Molin G, Albertsson P-A, Erlanson-Albertsson C. Feeding of spinach thylakoids to rat modulates the gut microbiota, decreases food intake and affects the insulin response. Journal of Nutritional Science 2013;2:1-9.
(5) Montelius C, Szwiec K, Kardas M, Lozinska L, Erlanson-Albertsson C, Pierzynowski S, Rehfeld JF, Weström B. Dietary thylakoids suppress blood glucose and modulate appetite-regulating hormones in pigs exposed to oral glucose tolerance test. Clinical Nutrition. 2014.

Elizabeth Maxim
Media Contact
Email Contact
Phone: +1 (310) 994-7381

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
As-a-service models offer huge opportunities, but also complicate security. It may seem that the easiest way to migrate to a new architectural model is to let others, experts in their field, do the work. This has given rise to many as-a-service models throughout the industry and across the entire technology stack, from software to infrastructure. While this has unlocked huge opportunities to accelerate the deployment of new capabilities or increase economic efficiencies within an organization, i...
The web app is agile. The REST API is agile. The testing and planning are agile. But alas, data infrastructures certainly are not. Once an application matures, changing the shape or indexing scheme of data often forces at best a top down planning exercise and at worst includes schema changes that force downtime. The time has come for a new approach that fundamentally advances the agility of distributed data infrastructures. Come learn about a new solution to the problems faced by software organ...
Through WebRTC, audio and video communications are being embedded more easily than ever into applications, helping carriers, enterprises and independent software vendors deliver greater functionality to their end users. With today’s business world increasingly focused on outcomes, users’ growing calls for ease of use, and businesses craving smarter, tighter integration, what’s the next step in delivering a richer, more immersive experience? That richer, more fully integrated experience comes ab...
Between the compelling mockups and specs produced by analysts, and resulting applications built by developers, there exists a gulf where projects fail, costs spiral, and applications disappoint. Methodologies like Agile attempt to address this with intensified communication, with partial success but many limitations. In his session at DevOps Summit, Charles Kendrick, CTO and Chief Architect at Isomorphic Software, will present a revolutionary model enabled by new technologies. Learn how busine...
Chris Van Tuin, Chief Technologist for the Western US at Red Hat, has over 20 years of experience in IT and Software. Since joining Red Hat in 2005, he has been architecting solutions for strategic customers and partners with a focus on emerging technologies including IaaS, PaaS, and DevOps. He started his career at Intel in IT and Managed Hosting followed by leadership roles in services and sales engineering at Loudcloud and Linux startups.
JFrog has announced a powerful technology for managing software packages from development into production. JFrog Artifactory 4 represents disruptive innovation in its groundbreaking ability to help development and DevOps teams deliver increasingly complex solutions on ever-shorter deadlines across multiple platforms JFrog Artifactory 4 establishes a new category – the Universal Artifact Repository – that reflects JFrog's unique commitment to enable faster software releases through the first pla...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 17th International Cloud Expo®, which will take place on November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet condit...
The last decade was about virtual machines, but the next one is about containers. Containers enable a service to run on any host at any time. Traditional tools are starting to show cracks because they were not designed for this level of application portability. Now is the time to look at new ways to deploy and manage applications at scale. In his session at @DevOpsSummit, Brian “Redbeard” Harrington, a principal architect at CoreOS, will examine how CoreOS helps teams run in production. Attende...
The buzz continues for cloud, data analytics and the Internet of Things (IoT) and their collective impact across all industries. But a new conversation is emerging - how do companies use industry disruption and technology enablers to lead in markets undergoing change, uncertainty and ambiguity? Organizations of all sizes need to evolve and transform, often under massive pressure, as industry lines blur and merge and traditional business models are assaulted and turned upside down. In this new da...
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult - let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and li...
The Internet of Things (IoT) is growing rapidly by extending current technologies, products and networks. By 2020, Cisco estimates there will be 50 billion connected devices. Gartner has forecast revenues of over $300 billion, just to IoT suppliers. Now is the time to figure out how you’ll make money – not just create innovative products. With hundreds of new products and companies jumping into the IoT fray every month, there’s no shortage of innovation. Despite this, McKinsey/VisionMobile data...
The APN DevOps Competency highlights APN Partners who demonstrate deep capabilities delivering continuous integration, continuous delivery, and configuration management. They help customers transform their business to be more efficient and agile by leveraging the AWS platform and DevOps principles.
There are so many tools and techniques for data analytics that even for a data scientist the choices, possible systems, and even the types of data can be daunting. In his session at @ThingsExpo, Chris Harrold, Global CTO for Big Data Solutions for EMC Corporation, will show how to perform a simple, but meaningful analysis of social sentiment data using freely available tools that take only minutes to download and install. Participants will get the download information, scripts, and complete en...
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at @DevOpsSummit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
The IoT market is on track to hit $7.1 trillion in 2020. The reality is that only a handful of companies are ready for this massive demand. There are a lot of barriers, paint points, traps, and hidden roadblocks. How can we deal with these issues and challenges? The paradigm has changed. Old-style ad-hoc trial-and-error ways will certainly lead you to the dead end. What is mandatory is an overarching and adaptive approach to effectively handle the rapid changes and exponential growth.